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The use of neuroimaging examinations is crucial in Alzheimer’s
disease (AD), in both research and clinical settings. Over the years,
magnetic resonance imaging (MRI)–based computer‐aided
diagnosis has been shown to be helpful for early screening and
predicting cognitive decline. Meanwhile, an increasing number of
studies have adopted machine learning for the classification of AD,
with promising results. In this review article, we focus on
computerized MRI‐based biomarkers of AD by reviewing
representative studies that used computerized techniques to
identify AD patients and predict cognitive progression. We
categorized these studies based on the following applications: (1)
identifying AD from normal control; (2) identifying AD from other
dementia types, including vascular dementia, dementia with Lewy
bodies, and frontotemporal dementia; and (3) predicting
conversion from NC to mild cognitive impairment (MCI) and from
MCI to AD. This systematic review could act as a state‐of‐the‐art
overview of this emerging field as well as a basis for designing
future studies.

© The authors 2021. This article is published with
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Creative Commons Non Commercial CC BY‐
NC: This article is distributed under the terms of the
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the SAGE and Open Access pages (https://us.sagepub.com/
en‐us/nam/open‐access‐at‐sage).
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Introduction

Alzheimer’s disease (AD), the most common
type of dementia, is a progressive disease
characterized by memory loss and overall
cognitive decline beyond normal aging. The
prevalence of dementia is increasing worldwide,
and in 2016, it became the fifth leading cause of
global deaths, as per the World Health

Organization (WHO) statistics [1]. According to
the World Alzheimer Report 2018, published by
Alzheimer’s Disease International, there are at
least 50 million people worldwide living with
AD or other dementias, and that number is
expected to triple to 152 million by 2050 [2].
In 2011, the National Institute on Aging and
Alzheimer’s Association (NIA‐AA) began incor‐
porating the use of biomarkers in the diagnostic
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Abbreviations
3D

three‐dimensional

LEAP

learning embeddings for atlas propagation

AD

Alzheimer’s disease

LPBM

linear programming boosting method

ADNI

Alzheimer’s Disease Neuroimaging Initiative

LR

logistic regression

AD‐RAI

AD resemblance atrophy index

LSR

large‐scale regularization

AE

autoencoders

MCI

mild cognitive impairment

aMCI

amnestic mild cognitive impairment

MIRIAD

Minimal Interval Resonance Imaging in Alzheimer’s
Disease

ANFIS

adaptive neuro‐fuzzy inference system

MR

magnetic resonance

ANN

artificial neural network

MXD

mixed VD–AD

AUC

area under the curve

NC

normal control

BS

Bayes statistics

ncMCI

mild cognitive impairment nonconverter

bvFTD

behavioral variant FTD

ncNC

normal control nonconverter

CBF

cerebral blood flow

NIA‐AA

National Institute on Aging and Alzheimer’s Association

CD

cognitively declining

NN

neural network

cMCI

MCI converter

OPLS

orthogonal projection to latent structures

cNC

NC converter

OR

odd ratio

CNN

convolutional neural network

PCA

principal component analysis

CS

cognitively stable

PET

positron emission tomography

CSF

cerebrospinal fluid

RAVENS

regional analysis of volumes examined in normalized space

DBM

deep Boltzmann machine

RBF

radial basis function

DBN

deep belief network

RBM

restricted Boltzmann machine

DLB

dementia with Lewy bodies

RLR

regularized logistic regression

DNN

deep neural network

RNN

recurrent neural network

DTI

diffusion tensor imaging

ROC

receiver‐operating characteristic

eMCI

early mild cognitive impairment

RVM

relevance vector machines

EN‐RLR

elastic net regularized logistic regression

SAE

stacked autoencoder

EOAD

early‐onset Alzheimer’s disease

SD

standard deviation

FA

fractional anisotropy

SEN

sensitivity

FDG‐PET

2‐[fluorine‐18]fluoro‐2‐deoxy‐D‐glucose PET

SGD

stochastic gradient descent

fMRI

functional magnetic resonance imaging

sMRI

structural magnetic resonance imaging

FTD

frontotemporal dementia

SPARE‐AD

Spatial Pattern of Abnormality for Recognition of Early
Alzheimer’s disease

GAN

generative adversarial networks

SPE

specificity

GM

gray matter

SPLS

sparse partial least squares

HMM

hidden Markov model

sVD

subcortical vascular dementia

iNPH

idiopathic normal pressure hydrocephalus

SVM

support vector machine

IWG

International Working Group

VaD

vascular dementia

LDA

linear discriminant analysis

VFI

voting features intervals

lMCI

late mild cognitive impairment

WHO

World Health Organization

leave one‐out cross‐validation

WMH

white matter hyperintensities

LOO‐CV
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criteria of AD [3]. In 2014, the International
Working Group (IWG) issued a revised
diagnostic criteria IWG‐2, which further
categorized the biomarkers into diagnostic and
progression biomarkers [4], among which tau
and amyloid‐β positron emission tomography
(tau‐PET and Aβ‐PET) are used for diagnosis,
whereas brain structural magnetic resonance
imaging (sMRI) and glucose metabolism
imaging (2‐[fluorine‐18]fluoro‐2‐deoxy‐D‐glucose
PET, or FDG‐PET) are used for monitoring the
progression of the disease. In 2018, the NIA‐AA
published the AT(N) research framework, which
proposed three groups of biomarkers: Aβ
deposition (A, based on cerebrospinal fluid [CSF]
or Aβ‐PET), pathologic tau (T, based on CSF
phosphorylated tau [p‐tau] or tau‐PET), and
neurodegeneration (N, based on FDG‐PET, CSF
total tau [t‐tau], or brain atrophy as measured
by MRI), which collectively define the various
stages of AD progression [5]. Although the 2018
NIA‐AA framework was not intended for
clinical diagnosis, it further emphasized the
importance of medical imaging for monitoring
disease progression and its prospect in early
screening for AD. Apart from the core bio‐
markers, emerging CSF and blood biomarkers
such as neurofilament light protein, neuron‐
specific enolase, and visinin‐like protein 1 might
be
feasible
for
detecting
AD‐related
neurodegeneration [6]. Other imaging modali‐
ties such as diffusion tensor imaging (DTI) [7],
arterial spin labeling [8], and functional MRI
(fMRI) [9] have also shown great prospects in
the research of preclinical AD.
In this review article, we focus on the
following aspects of computerized MRI‐based
biomarkers of AD: (1) identifying AD from
normal control (NC), (2) identifying AD from
other dementia types, including vascular
dementia (VaD), dementia with Lewy bodies
(DLB), and frontotemporal dementia (FTD), and

(3) predicting the conversion from NC to mild
cognitive impairment (MCI) and from MCI to
AD.

2

MRI biomarkers used in identifying
AD from NC

With regard to the algorithms used for
identifying AD from NC, research has been
conducted on machine learning, deep learning,
or a combination of both approaches. In some
studies, modalities other than MRI, such as PET
and cerebrospinal fluid (CSF), were also
integrated into the AD/NC classification. Most
studies used sMRI as the magnetic resonance
(MR) modality. Among these sMRI studies,
density maps, cortical surface, and predefined
region–based methods were the main extraction
methods used in machine‐learning studies,
whereas the image patch‐based method is
another common method used in deep‐learning
studies.
2.1

AD/NC
learning

classification

using

machine

In their review, Rathore et al. [10] categorized
the MRI‐based AD classification studies into
sMRI, fMRI, and DTI.
For the sMRI biomarkers of AD, the
hippocampus has always played an important
role and is considered to be a crucial region that
aids in the diagnosis of AD. In particular,
hippocampal volume has been validated and
accepted by the Coalition Against Major
Diseases/European Medicines Agency as the
neuroimaging biomarker for trials targeting
predementia stages [11]. In addition, other
regions have shown significant atrophy or
volumetric differences between AD and NC [12,
13]. Therefore, studies using predefined region‐
based methods have used hippocampal features
and biologically selected features beyond the
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hippocampus for classification.
Using spherical harmonics to model the shape
of the hippocampus, Gerardin et al. [14]
detected an accuracy of 94% for the classification
of AD/NC. Li et al. [15] quantified the
hippocampal
shape
using
surface‐based
anatomic mesh modeling and reported an
accuracy of 94.9%. After constructing a statistical
shape model for the hippocampus, She et al. [16]
reported an accuracy of 88.3%. Wang et al. [17]
demonstrated an accuracy of 81.1% using a
large‐deformation diffeomorphic and momentum‐
based hippocampal shape. Sørensen et al. [18]
used hippocampal texture to yield an area under
the curve (AUC) of 0.912 in discriminating AD
from NC.
Among studies using biologically selected
features beyond the hippocampus, Chincarini et
al. [19] achieved an AUC of 0.97 using temporal
lobe structures that are known to be affected in
early AD, such as the entorhinal cortex,
perirhinal cortex, hippocampus, and parahippo‐
campal gyri. In addition, Spulber et al. [20] used
supervised multivariate data analysis and
orthogonal projection to latent structures (OPLS)
for statistical learning, yielded an accuracy of
88.4% for the AD/NC classification using cortical
thickness and volumetric features. In a more
recent study, Mai et al. [21] combined the degree
of atrophy of multiple brain structures into an
AD resemblance atrophy index (AD‐RAI) and
evaluated its performance among groups of
AD/NC and subgroups of AD/NC that were
assessed
with
AT(N)
biomarkers
and
demonstrated accuracies of 91% and 100%,
respectively.
In addition to predefined region‐based
methods, density maps and cortical surface are
other main feature extraction methods that can
be used in sMRI for AD/NC classification. In
studies using the density map‐based method,
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researchers used either whole‐density maps
[22–27] or reduced‐density maps as features,
which are features that have been reduced using
supervised or unsupervised feature‐reduction
methods [28–30] or features that have been
extracted from predefined atlases [31] or
adaptive regions to reduce dimensionality
[32–34]. For studies using the surface‐based
method, the authors used supervised/
unsupervised feature reduction‐based methods
[35, 36] or atlas‐based methods to reduce
vertices as features [37–42].
For fMRI studies distinguishing AD from NC,
the authors used features that were based on
graph theory‐based measures [43] or functional
connectivity [44]. In the DTI studies, features
were extracted based on tractography [45],
connectivity network measures [46], and
discriminative voxel selection [47].
Table 1 presents a summary of MRI studies
for identifying AD from NC.
2.2 AD/NC classification using deep learning
for feature selection from neuroimaging
data
In the systematic review by Jo et al. [48], the
authors identified studies combining traditional
machine learning and deep learning, with the
latter responsible for the feature selection from
the images (Table 2). By using the gray matter
(GM) tissue volume from MRI, as well as the
mean intensity from PET and CSF biomarkers of
Aβ42, t‐tau, and p‐tau as features, Suk et al. [49]
used a stacked autoencoder (SAE) to discover a
latent feature representation and adopted a
multikernel support vector machine (SVM) for
classification to achieve an accuracy of 95.9%.
These same authors [50] used a deep Boltzmann
machine (DBM) to demonstrate an accuracy of
95.35% by using the tissue densities of an MRI
patch and the voxel intensities of a PET patch as
observations. Later, they combined SAE‐learned
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Table 1 Summary of studies on AD/CN classification using machine learning. cMCI/ncMCI classification performance is shown
when applicable.

sMRI (density map based)

SVM

AD/NC
cMCI/ncMCI
AD CN
cMCI ncMCI
accuracy
accuracy
95
20 20

sMRI (density map based)

SVM

92.9

14

14

sMRI (density map based)

SVM

81.1

33

57

Casanova et al. (2011) [23]

sMRI (density map based)

LSR

85.7

49

49

Hinrichs et al. (2009) [24]

sMRI (density map based)

LPBM

82

89

94

Termenon & Graña (2012) sMRI (density map based)
[25]

RVM, SVM

83

49

49

Plant et al. (2010) [26]

sMRI (density map based)

SVM, BS, VFI

92

32

18

Möller et al. (2016) [27]

sMRI (density map based)

SVM

88

84

94

Liu et al. (2013) [28]

sMRI (density map based)

RLR, SVM, LDA

90

86

Salvatore et al. (2015) [29]

sMRI (density map based)

SVM

Beheshti & Demirel (2015) sMRI (density map based)
[30]
Magnin et al. (2009) [31]
sMRI (density map based)
Fan et al. (2008) [32]

Study
Kloppel et al. (2008)[22]

MR modality

Classifier

75

9

15

137 68

97

93

76

137 162 66

76

134

SVM

89.65

130 130

SVM

94.5

16

22

sMRI (density map based)

SVM

94.3

56

66

Min et al. (2014) [33]

sMRI (density map based)

SVM

91.64

97

128 72.41

117

117

Liu et al. (2015) [34]

sMRI (density map based)

SVM

92.51

97

128 78.88

117

117

Cho et al. (2012) [35]

sMRI (surface based)

LDA

88.33

128 160 71.21

72

131

Park et al. (2012) [36]

sMRI (surface based)

SVM

90

25

50

Desikan et al. (2009) [37]

sMRI (surface based)

LR

95

65

94

McEvoy et al. (2009) [38]

sMRI (surface based)

LDA

89

84

139

Oliveira et al. (2010) [39]

sMRI (surface based)

SVM

88.2

14

20

Eskildsen et al. (2013) [40]

sMRI (surface based)

LDA

86.7

194 226 71.1

340

134

Wee et al. (2013) [41]

sMRI (surface based)

Multikernel SVM 92.35

198 200 75.05

89

111

Lillemark et al. (2014) [42]

sMRI (surface based)

LDA

114 170

Wang et al. (2007) [17]

sMRI (predefined region based) LR

87.70
(AUC)
81.1

18

26

Li et al. (2007) [15]

sMRI (predefined region based) SVM

94.9

19

20

Gerardin et al. (2009) [14]

sMRI (predefined region based) SVM

94

23

25

Shen et al. (2012) [16]

sMRI (predefined region based) Bagged SVM

88.3

99

138

Sørensen et al. (2016) [18]

sMRI (predefined region based) SVM

101 169 74.20 (AUC)

93

140

Chincarini et al. (2011) [19]

sMRI (predefined region based) SVM

144 189 74.00 (AUC)

136

166

Mai et al. (2021) [21]

sMRI (predefined region based) ROC

91.20
(AUC)
97.00
(AUC)
91

50

50

Chen et al. (2011) [44]

fMRI

Fisher LDA

82.00

20

20

Khazaee et al. (2015) [43]

fMRI

SVM

100

20

20

Nir et al. (2015) [45]

DTI

SVM

80.6

37

50

Prasad et al. (2015) [46]

DTI

SVM

78.2

38

50

38

74

Dyrba et al. (2013) [47]

DTI

SVM

83

137 143
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Table 2 Summary of studies on the prediction of NC‐to‐MCI or MCI‐to‐AD conversion. AD/NC classification performance is shown when
applicable.

Study

MR modality

Other
modality

Suk & Shen

sMRI (density PET, CSF

(2013) [49]

map based)

Suk et al.

sMRI (image

(2014) [50]

patch based)

Machine
learning/deep

Data
processing/

learning
Hybrid

Classifier

training
SAE

SVM

AD/NC
accuracy
95.9

cMCI/
ncMCI

Groups

accuracy
75.8

51 AD 43 cMCI
56 ncMCI 52 NC

PET

Hybrid

DBM

SVM

95.35

75.92

93 AD 76 cMCI
128 ncMCI 101
NC

Li et al.

sMRI

(2015) [52]

(predefined

PET, CSF

Hybrid

RBM + dropout SVM

91.4

57.4

51 AD 43 cMCI
56 ncMCI 52 NC

region based)
Suk et al.

sMRI

(2015) [51]

(predefined

PET, CSF

Hybrid

SAE + sparse

SVM

98.8

83.3

learning

51 AD 43 cMCI
56 ncMCI 52 NC

region based)
Liu et al.

sMRI

(2014) [53]

(predefined

PET

Pure deep

SAE + NN

Softmax

65 AD 67 cMCI

87.76

102 ncMCI 77

learning

region based)

NC

Li et al.

sMRI (density PET

Pure deep

(2014) [61]

map based)

learning

3D CNN

Logistic

198 AD 167

92.87

cMCI 236 ncMCI

regression

229 NC
Liu et al.

sMRI

(2015) [54]

(predefined

PET

Pure deep

SAE with zero

learning

masking

Softmax

77 AD 67 cMCI

91.4

102 ncMCI 85

region based)

NC

Cheng et al.

sMRI (image

Pure deep

(2017) [56]

patch based)

learning

Cheng & Liu

sMRI (image

(2017) [57]

patch based)

Aderghal et al.
(2017) [59]

3D CNN

Softmax

87.15

199 AD, 229 NC

Softmax

89.64

93 AD, 100 NC

Softmax

91.41

188 AD 399 MCI

Pure deep

3D CNN + 2D

learning

CNN

sMRI

Pure deep

2D CNN

(predefined

learning

PET

228 NC

region based)
Korolev et al.

sMRI (image

Pure deep

(2017) [58]

patch based)

learning

Vu et al.

sMRI (image

(2017) [62]

patch based)

PET

Pure deep

3D CNN

Softmax

50 AD 43 lMCI

80

77 eMCI 61 NC
SAE + 3D CNN Softmax

91.14

91.09

145 AD 172 NC

learning

Liu et al.

sMRI (image

Pure deep

Landmark

(2018) [60]

patch based)

learning

detection + 3D

239 ncMCI 200

CNN

NC

Lu et al.
(2018) [55]

sMRI (image
patch region
based)

deToledo‐
Morrell et al.
(2004) [79]

sMRI
(predefined
region based)

PET

Softmax

Pure deep
learning

DNN + NN

Softmax

Machine
learning

Self‐developed
volume
quantification
protocol

Multivariate
logistic
regression

84.6

76.9

159 AD 38 cMCI

82.93

238 AD 217
cMCI 409 ncMCI
360 NC

93.5

10 cMCI 17
ncMCI

(To be continued on the next page)
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Study
Clerx et al.
(2013) [80]

MR modality
sMRI
(predefined
region based)

Other
modality

Machine
learning/deep
learning
Machine
learning

Data processing/
training
Manual and
automated
atlas‐based
segmentation

Classifier

AD/NC
accuracy

ROC

cMCI/
ncMCI

Groups

accuracy
0.71 (AUC
for manual
hippocamp
us)
0.71 (AUC
for LEAP
hippocamp
us)
81.5

30 cMCI 126
ncMCI (dataset
1)
61 cMCI 111
ncMCI (dataset
2)

Misra et al.
(2009) [81]

sMRI
(predefined
region based)

Machine
learning

RAVENS

High‐dimens
ional pattern
classification

Spulber et al.
(2013) [20]

sMRI
(predefined
region based)

Machine
learning

FreeSurfer

Supervised 88.4
multivariate
data
analysis,
statistical
learning
(OPLS)

67.7

Zhao et al.
(2019) [82]

sMRI
(predefined
region based)

Machine
learning

AccuBrain

ROC

Davatzikos et al. sMRI
(2009) [68]
(predefined
region based)

Machine
learning

RAVENS

High‐dimens 0.885
ional pattern (MCI/NC
classification AUC)

0.771
25 AD 35 cMCI
(AUC)
50 ncMCI 23
0.740 (cNC/ cNC 50 ncNC
ncNC AUC)
56 AD 66 NC
(Training), 15
ncMCI 109 NC
(Testing)

RAVENS (MRI
processing)

SVM (High‐
dimensional
pattern cla‐
ssification)

Clark et al.
(2012) [85]

sMRI
(predefined
region based)

PET, CBF Machine
learning

Bangen et al.
(2018) [83]

sMRI
(predefined
region based)

Machine
learning

27 cMCI 76
ncMCI

295 AD 173
cMCI 261 ncMCI
335 NC

86 (CS/CD) 143 NC (25 CS,
25 CD)

Manual and
Logistic
multiatlas
regression
segmentation
(WMH as quartiles)

2.04 (cNC/
ncNC OR)

489 ncNC 72
cNC

Manual and
multiatlas
segmentation
(hippocampal
volume as quartiles)

2.13 (cNC/
ncNC OR)

489 ncNC 72
cNC

Manual and
multiatlas
segmentation
(total brain volume
change rate as
quartiles)

3.03 (cNC/
ncNC OR)

435 ncNC 56
cNC

Manual and
multiatlas
segmentation
(continuous
hippocampal
volume change rate)

0.68 (cNC/
ncNC OR)

449 ncNC 42
cNC (conversion
to aMCI)
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feature representation with the original
low‐level features from multimodality fusion
via multikernel SVM and showed the highest
accuracy of 98.8% in semisupervised learning
[51]. Li et al. [52] used volumetric features from
MRI and PET images and CSF biomarkers of
Aβ42, t‐tau, and p‐tau, via the restricted
Boltzmann machine (RBM) with dropout and
SVM as a classifier, to obtain an accuracy of
91.4%.
2.3 Deep learning for classification of AD and
NC
Jo et al. [48] also identified several studies that
used only deep learning for identifying AD from
NC (Table 2). Liu et al. [53] used SAE and a
softmax output layer to yield an accuracy of
87.76% for the classification of AD/NC. Liu et al.
[54] proposed a framework using SAE and a
softmax logistic regressor and applied a
zero‐mask method to achieve an accuracy of
91.4%. Lu et al. [55] used a deep neural network
(DNN) and obtained an accuracy of 84.6%.
Cheng et al. [56] proposed the construction of
multiple deep three‐dimensional (3D) convolu‐
tional neural networks (CNNs) and reported an
accuracy of 87.15%. Later, they proposed the
construction of cascaded CNNs (3D CNN + 2D
CNN) and achieved an accuracy of 89.64% [57].
Using residual and plain 3D CNN architectures
without intermediate handcrafted feature
extraction, Korolev et al. [58] reported an
accuracy of 80%. Aderghal et al. [59] proposed a
multiprojection fusion approach using CNNs
and demonstrated an accuracy of 91.41%. Liu et
al. [60] proposed a landmark‐based deep
multi‐instance learning framework to achieve
accuracies of 91.09% and 92.75% from the
Alzheimer’s Disease Neuroimaging Initiative
(ADNI)‐2 and Minimal Interval Resonance
Imaging in Alzheimer’s Disease (MIRIAD),
respectively. Li et al. [61] designed a 3D CNN

http://bsa.tsinghuajournals.com

architecture and yielded an accuracy of 92.87%.
Vu et al. [62] used SAE and 3D CNN and
demonstrated an accuracy of 91.1%.

3

MRI biomarkers in differentiating AD
from other dementia types

Table 3 provides a list of studies classifying AD
versus DLB, FTD, and VaD. All of the examined
studies used machine learning to differentiate
AD from other dementia types. The MR
modalities used in these studies include sMRI,
DTI, and fMRI.
3.1 Classification between AD and DLB
One of the supportive biomarkers, according to
the 2017 revised criteria for the clinical diagnosis
of DLB, is a relative preservation of medial
temporal

lobe

structures

on

computed

tomography or MRI scan [63]. To differentiate
DLB from AD, Matsuda et al. [64] investigated
the local atrophy of the medial temporal lobe
and brainstem and reported accuracies of 73.4%
and

63.3%

in

the

receiver‐operating

characteristic (ROC) analyses for the training
and testing sets, respectively. Lebedev et al. [65]
used the sparse partial least squares regression
(SPLS) classification using cortical thickness and
achieved AUCs of 0.948 and 0.731 for the
training and testing sets, respectively.
3.2 Classification between AD and FTD
To differentiate AD from FTD, Kim et al. [66]
used principal component analysis (PCA) and
linear discriminant analysis (LDA) classifiers
and achieved an accuracy of 90.8% based on
cortical thickness. By using the GM density map
as a feature, Möller et al. [27] used SVM for the
classification to show a training accuracy of 79%,
whereas single‐subject diagnosis in the pre‐
diction set yielded 82% accuracy when using the
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Table 3 Summary of studies on the classification between AD and other types of dementia.
Study

Type of non‐AD
dementia

Lebedev et al. (2013) [65]

DLB

Matsuda et al. (2019) [64]

DLB

Kim et al. (2019) [66]

FTD

Möller et al. (2016) [27]

FTD

sMRI (density
map based)

Raamana et al. (2014) [67]

FTD

Davatzikos, et al. (2008)
[68]
Du et al. (2007) [69]

FTD
FTD

Canu et al. (2017) [70]

FTD

Yu et al. (2021) [71]

FTD

Palesi et al. (2018) [73]

VaD

sMRI (predefined
region based)
sMRI (predefined
region based)
sMRI (surface
based)
sMRI (surface
based), DTI
sMRI (predefined
region based)
DTI

Goujon et al. (2018) [75]

VaD

DTI

Zarei et al. (2009)[74]

VaD

DTI

Zheng et al. (2019) [76]

VaD

Castellazzi et al. (2020)
[77]

VaD

MR modality
sMRI (surface
based)
sMRI (predefined
region based)
sMRI (surface
based)

Classifier
SPLS
ROC
PCA + LDA
hierarchical
classification
SVM

SVM + RBF kernel
SVM

AD/non‐AD accuracy
0.731 (testing AUC),
0.948 (training AUC)
63.3 (testing AUC),
73.4 (training AUC)
90.8 (FTD/AD), 75.8
(overall)
79 (training), 82
(single subject)

65 (train/test), 72
(LOO‐CV)
84.3

Groups
97 DLB, 97AD
239 DLB, 385 AD (414
training, 210 testing)
143 FTD, 50AD, 146 NC

84 AD, 51 bvFTD, 94 NC
(training: 42 AD, 26 bvFTD,
47 NC; testing: 42 AD, 25
bvFTD, 47 NC)
34 AD,30 bvFTD, 14 NC)

LOO‐CV of the
logistic regressions
Random Forest

82

37 AD, 37 NC; 12 FTD, 12
NC
23 NC, 22 AD, 19 FTD

82

62 EOAD, 27 bv FTD, 48 NC

ROC

0.93 (AUC)

50 AD, 50 FTD (validation
dataset)
31 AD, 27 VaD, 35 NC

ROC from stepwise 75.9
discriminant
analysis
ROC
0.995 (AUC)

Discriminant
analysis model in
stepwise approach
sMRI (predefined SVM + RBF
region based)
fMRI, DTI
ANFIS (best);
ANN, SVM

discrimination maps. By studying the volume,
surface displacement, and Laplacian invariants
of the hippocampus and lateral ventricle,
Raamana et al. [67] applied k‐means clustering
for dimensionality reduction and used SVM
with radial basis function (RBF) kernel for
classification. When using left ventricular
displacements as features, these authors
reported 72% accuracy from leave‐one‐out
cross‐validation (LOO‐CV) classification and
65% accuracy from the train/test classification.
In addition, they achieved a three‐class AUC of
0.76 using bilateral ventricular displacement as
features, which is the first multiclass

87.5

30 iNPH, 30AD, 30 sVD, 30
NC
13 VaD, 16 AD, 22 NC

84.35

58 AD, 35 VaD

85.25

33 AD, 27 VD

77.33

15 MXD (mixed VD–AD
with 3‐year follow‐up)

classification study among AD, FTD, and NC.
Using regional analysis of volumes examined in
normalized space (RAVENS) for image
processing and PCA for feature selection,
Davatzikos et al. [68] selected features from
different brain regions and reported an accuracy
of 84.3% from SVM classification. Du et al. [69]
studied the cortical thickness and yielded 82%
accuracy from LOO‐CV of logistic regression.
Canu et al. [70] conducted a multimodal MRI
study by combining the cortical thickness and
diffusion tensor measures and was able to
distinguish patients with early‐onset Alzhei‐
mer’s disease (EOAD) and those with FTD with

https://mc03.manuscriptcentral.com/brainsa

| Brain Science Advances

35

Brain Sci. Adv.

82% accuracy from random forest analysis.
Recently, by incorporating volumetric indexes in
FTD‐dominant regions, Yu et al. [71] developed
the frontotemporal dementia index and
achieved an AUC of 0.93, as validated in
independent data from ADNI and the
Frontotemporal Lobar Degeneration Neuro‐
imaging Initiative database.
3.3 Classification between AD and VaD
The existence of overlap between pathology of
AD and VaD is widely accepted [72]. Therefore,
it is crucial to obtain a reliable method of
distinguishing these two types of dementia. By
using fractional anisotropy (FA) values of
multiple regions as features, Palesi et al. [73]
classified AD and VaD with 75.9% accuracy
from a stepwise discriminant analysis. Zarei et
al. [74] showed their highest accuracy of 87.5%
from a combined discriminant analysis model
based on transcallosal prefrontal FA values and
Fazekas score. Goujon et al. [75] achieved their
highest AUC of 0.995 using apparent diffusion
coefficient values in the parietal periventricular
region as features. Zheng et al. [76] used SVM
with RBF kernel for classification and yielded an
accuracy of 84.35% using structural MRI
biomarkers obtained by AccuBrain® as input
features. In their recent study, Castellazzi et al.
[77] tested three machine‐learning algorithms:
artificial neural network (ANN), SVM, and
adaptive neuro‐fuzzy inference system (ANFIS),
with both structural and functional information
used as input features. When providing
multiple regional metrics from resting‐state
fMRI and DTI as inputs, ANFIS was the most
efficient algorithm for discriminating AD from
VaD, which yielded an accuracy of 85.25%. In
addition, when applying the best discriminant
pattern to patients diagnosed with mixed
VaD‐AD dementia (who converted to AD or
VaD at the 3‐year follow‐up), ANFIS showed
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77.33% accuracy in predicting the underlying
disease based on the baseline data, which
demonstrates the potential for early detection on
the typology of dementia.

4

Prediction of cognitive conversion from
NC to MCI and from MCI to AD

Although many studies have targeted the
identification of MCI subjects at risk of AD, few
studies have involved the prediction of
conversion from NC to MCI. With regard to the
algorithms used for predicting disease
progression, machine learning, deep learning, or
a combination of both approaches have been
reported. sMRI was the mostly used MR
modality in the examined studies. Some of the
studies mentioned in Section 2 also predicted
MCI to AD conversion (Table 1 and Table 2).
4.1 Machine learning for prognostic prediction
Similar to the AD/NC classification, we found
that the hippocampus and several AD‐related
regions were commonly used biomarkers for the
prediction of cognitive conversion from MCI to
AD. Several predefined region‐based studies
mentioned in Section 2.1 also applied their
classification algorithms to the prediction of the
conversion from MCI to AD. Sørensen et al. [18]
used hippocampal texture as a predictor of
MCI‐to‐AD conversion and obtained an AUC of
0.742. Chincarini et al. [19] computed a single
index combining local analysis of several
regions and yielded an accuracy of 0.74. In
addition, by quantifying entorhinal volume
using their developed protocol, Goncharova et
al. [78] and deToledo‐Morrell et al. [79] used
multivariate logistic regression to achieve their
best concordance rate of 93.5% of MCI to AD
conversion. Plant et al. [26] investigated the
performance of three types of classifier and
obtained their best prediction accuracy of 75% of
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MCI‐to‐AD conversion when using voting
features intervals (VFI), in which the anterior
cingulate gyrus and orbitofrontal cortex were
the best features. Clerx et al. [80] studied the use
of the hippocampus, medial temporal lobe
atrophy score, and lateral ventricle as features
and yielded the best AUC of 0.71 using the
hippocampus segmented either manually or
using the Learning Embeddings for Atlas
Propagation (LEAP) method. Misra et al. [81]
achieved a prediction accuracy of 81.5% for the
MCI‐to‐AD
conversion
using
a
high‐
dimensional pattern classification of brain
atrophy. By using supervised multivariate data
analysis and OPLS for statistical learning,
Spulber et al. [20] used brain regions segmented
from FreeSurfer as features and used AD/CN
and cMCI/ncMCI as the training set and testing
set, respectively, which yielded an accuracy of
67.7% for the MCI‐to‐AD conversion. By using
their AD‐RAI index, which combined the
atrophy degree of multiple brain structures,
Zhao et al. [82] yielded an AUC of 0.771 for the
MCI‐to‐AD conversion.
In addition to the predefined region‐based
methods, several density maps and cortical
surface‐based sMRI studies mentioned in
Section 2.1 also applied their classification
algorithms in predicting the conversion from
MCI to AD. Among the sMRI studies using the
density map‐based method, Liu et al. [28] used
embedded MRI features of regional brain
volume and cortical thickness and reported an
accuracy of 68%. Salvatore et al. [29]
implemented PCA coupled with a Fisher
discriminant ratio criterion to MR images
(whole‐brain, GM, and white matter) and
obtained an accuracy of 66%. Min et al. [33]
extracted adaptive regional features and yielded
an accuracy of 72.41%. Liu et al. [34] proposed a
novel view‐centralized multiatlas classification
method and achieved an accuracy of 78.88% for

cMCI/ncMCI classification. Among the sMRI
studies using a cortical surface‐based method,
Cho et al. [35] demonstrated an accuracy of
71.21% based on the incremental method using a
spatial frequency representation of cortical
thickness data. Eskildsen et al. [40] used
patterns of cortical thickness measurements for
the cMCI/ncMCI classification and reported an
accuracy of 71.1%. By integrating the correlative
morphological information with region of
interest‐based information via multikernel SVM,
Wee et al. [41] achieved an accuracy of 75.05%.
Last but not least, among the DTI studies,
Prasad et al. [46] reported an accuracy of 63.4%
for cMCI/ncMCI classification by combining the
fiber network measures and the flow network
measures (Table 1).
With regard to the conversion of NC to MCI,
Bangen et al. [83] demonstrated that baseline
measures of white matter hyperintensities
(WMH)

and

hippocampal

volume

were

associated with a higher odds of conversion
from normal cognition to MCI at 6.5‐year
follow‐up. In addition, they found that the
annualized change rates in total cerebral brain
volume

and

hippocampal

volume

were

associated with a higher odd of conversion from
normal cognition to MCI at follow‐up. Using a
composite index of multiple MRI features, Zhao
et al. [82] reported an AUC of 0.740 for the
NC‐to‐MCI conversion, which demonstrated for
the first time that such an index could also
differentiate

normal

subjects

at

risk

of

conversion to MCI over a 2‐year period. Several
other studies also applied a composite index of
multiple MRI features to longitudinal data from
NC. For instance, by using their spatial pattern
of abnormality for the recognition of early
Alzheimer’s disease (SPARE‐AD) index of brain
atrophy, Davatzikos et al. [84] evaluated the
longitudinal progression of SPARE‐AD in NC
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and MCI and were able to distinguish these

5

Discussion

using the rate of SPARE‐AD change, which
achieved an AUC of 0.89. Later, by combining
MRI and resting PET cerebral blood flow (CBF)
images, Clark et al. [85] used the resulting index,
the

spatial

pattern

of

abnormality

for

recognition of early cognitive decline, to predict
subsequent cognitive decline in cognitively
normal older adults. Using a combination of
MRI and [15O] PET CBF data, they classified
cognitively stable (CS) and cognitively declining
(CD) individuals with 86% accuracy, using
leave‐two‐out cross‐validation. Overall, despite
the lack of studies predicting the conversion
from NC to MCI using MRI‐based biomarkers, it
is encouraging that there are multiple ongoing
longitudinal studies exploring different neuro‐
imaging biomarkers in people with subjective
cognitive decline [86–89].
4.2 Prognostic prediction using deep learning
for feature selection from neuroimaging
data
The studies mentioned in Section 2.2 also
applied their classification algorithms for the
prediction of the MCI‐to‐AD conversion. Suk et
al. [49] used the SAE and SVM as classifiers to
yield an accuracy of 75.8%. The authors also
demonstrated an accuracy of 75.92% in a study
using the DBM [50] and an accuracy of 83.3% in
another study using SAE [51]. By applying the
RBM with a dropout technique, Li et al. [52]
obtained an accuracy of 57.4%.
4.3 Deep learning for prognostic prediction
Two of the studies mentioned in Section 2.3 also
used pure deep learning for the prediction of
MCI to AD conversion. Lu et al. [55] used DNN
to yield an accuracy of 82.93% for the
MCI‐to‐AD conversion. Liu et al. [60] used
landmark detection and 3D CNN to obtain an
accuracy of 76.9%.
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In this review article, we focused on
computerized MRI‐based biomarkers of AD, for
which we identified representative studies using
machine learning, deep learning, or a
combination of both approaches. Deep learning
has the ability to detect complex nonlinear
relationships and interactions between variables
and has been shown to yield excellent
performance in identifying AD from NC and
predicting the conversion from MCI to AD.
Nonetheless, its black box nature may prevent
researchers from clearly understanding its
models. In addition, the ability to model
nonlinearities and interactions makes deep
learning easily prone to overfitting, and training
a DNN that generalizes well to new data could
be a challenge. Last but not least, deep learning
could be much more computationally expensive
than machine learning.
Meanwhile, traditional machine learning is
relatively better for understanding the effect of
features on the classification outcome, which
makes it easier to interpret the importance of
certain brain features that are extracted from the
images. However, for feature extraction and
selection, expert knowledge might be required,
whereas deep‐learning‐based classification could
be performed using automated selection of
features or without feature selection. From this
review, we found that traditional machine
learning still appears to be widely used in
studies of computerized MRI‐based biomarkers
of AD, ranging from the classification between
AD and NC, and between AD and other
dementia types, to the prediction of NC‐to‐MCI
and MCI‐to‐AD conversion.
One of the limitations of this review is that the
classification performance metrics of most
studies were reported only in terms of accuracy
(or AUC when accuracy is not available).
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However, a high accuracy does not necessarily
indicate good performance. Since these studies
had different sample sizes, group composition,
and data sets, a fair comparison cannot be made
based only on classification accuracy. Thus,
when interpreting and comparing the
classification performance of different studies, it
is essential to consider factors beyond accuracy.
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